Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173124 | 0.88 | MEN1 (0.59) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12189466 | 0.85 | KDM5A (0.53) | LRRK2MRGPRX4SGMS2KMT2AEGFR | |
| SCHEMBL12173159 | 0.84 | MRGPRX4 (0.52) | LRRK2MRGPRX4SGMS2MEN1KMT2A | |
| SCHEMBL12173161 | 0.81 | MEN1 (0.53) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12173118 | 0.80 | MRGPRX4 (0.55) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12172997 | 0.79 | PARP1 (0.61) | LRRK2MRGPRX4SGMS2MEN1KMT2A | |
| SCHEMBL12173117 | 0.78 | MEN1 (0.54) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12173126 | 0.78 | MRGPRX4 (0.53) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12173138 | 0.78 | POLB (0.53) | LRRK2MRGPRX4MEN1KMT2AEGFR | |
| SCHEMBL12173176 | 0.77 | MRGPRX4 (0.53) | LRRK2MRGPRX4MEN1KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | LRRK2 3721/4885MRGPRX4 2390/4885SGMS2 4188/4885 |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | LRRK2 3721/4885MRGPRX4 2390/4885SGMS2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.